Table 1.
Characteristics | Training Cohort (n=253) | Validation Cohort (n=163) | P value |
---|---|---|---|
Age, years | 0.871 | ||
Median [range] | 61 [38, 85] | 64 [44, 85] | |
Sex, no. (%) | 0.382 | ||
Male | 206/253(81.4%) | 127/163 (77.9%) | |
Female | 47/253(18.6%) | 36/163 (22.1%) | |
Smoking, no. (%) | 0.354 | ||
Yes | 186/253 (73.5%) | 113/163 (69.3%) | |
No | 67/253 (26.5%) | 50/163 (30.7%) | |
Site, no. (%) | 0.089 | ||
LUL | 64/253 (25.3%) | 43/163 (26.4%) | |
LLL | 65/253 (25.7%) | 54/163 (33.1%) | |
RUL | 65/253 (25.7%) | 22/163 (13.5%) | |
RML | 7/253 (2.8%) | 5/163 (3.1%) | |
RLL | 52/253 (20.5%) | 39/163 (23.9%) | |
Location, no, (%) | 0.815 | ||
Central | 115/253 (45.5%) | 76/163 (46.6%) | |
Peripheral | 138/253 (54.5%) | 87/163 (53.4%) | |
GTV (cm3) | 0.809 | ||
I | 15.63 [4.35–51.23] | 14.32 [2.85–49.89] | |
II | 50.14 [13.88–145.18] | 43.75 [15.83–186.45] | |
III | 109.33 [34.95–361.61] | 115.43 [33.58–428.33] | |
AJCC stage*, no, (%) | 0.974 | ||
IA | 39/253 (15.4%) | 24/163 (14.7%) | |
IB | 46/253 (18.2%) | 31/163 (19.0%) | |
IIA | 31/253 (12.2%) | 20/163 (12.3%) | |
IIB | 26/253 (10.3%) | 16/163 (9.8%) | |
IIIA | 50/253 (19.8%) | 33/163 (20.3%) | |
IIIB | 61/253 (24.1%) | 39/163 (23.9%) | |
T stage*, no, (%) | 0.106 | ||
1a | 29/253 (11.5%) | 15/163 (9.2%) | |
1b | 25/253 (9.9%) | 15/163 (9.2%) | |
2a | 90/253 (35.6%) | 48/163 (29.4%) | |
2b | 31/253 (12.2%) | 21/163 (12.9%) | |
3 | 46/253 (18.2%) | 41/163 (25.2%) | |
4 | 32/253 (12.6%) | 23/163 (14.1%) | |
N stage, no, (%) | 0.839 | ||
0 | 112/253 (44.3%) | 65/163 (39.9%) | |
1 | 46/253 (18.2%) | 39/163 (23.9%) | |
2 | 54/253 (21.3%) | 36/163 (22.1%) | |
3 | 41/253 (16.2%) | 23/163 (14.1%) |
Note: Age and Volume are represented as median and ranges.
Abbreviations: ADC, adenocarcinoma; SCC, squamous cell carcinoma; AJCC stage*, AJCC stage subgroup; T state*, the T stage subgroup; LUL, left upper lobe; LLL, left lower lobe; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe.